This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clemons, K. V.
Right arrow Articles by Stevens, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clemons, K. V.
Right arrow Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3433-3436, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3433-3436.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice

Karl V. Clemons* and David A. Stevens

California Institute for Medical Research and Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California 95128, and Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305

Received 22 December 2000/Returned for modification 18 January 2001/Accepted 12 September 2001

A model of orogastric candidosis in SCID mice, which mimics disease seen in AIDS patients, was used to evaluate ravuconazole in comparison with fluconazole for treatment. Mice were infected orally with Candida albicans and received either no treatment or oral treatment once daily for 12 days with 1, 5, or 25 mg of ravuconazole per kg of body weight per day, 5 or 25 mg of fluconazole per kg per day, or diluent (10% dimethyl sulfoxide in 0.5% carboxymethyl cellulose). The numbers of C. albicans CFU in the esophagus, stomach, small intestine, and cecum on day 25 in mice given no treatment and diluent were equivalent. Both doses of fluconazole significantly reduced numbers of CFU in all four tissues but were equivalent to each other. Ravuconazole showed dose-responsive improvement of clearance of CFU. Ravuconazole at 25 mg/kg was superior in reduction of numbers of CFU in all tissues to controls or 25 mg of fluconazole per kg and to other regimens in at least three tissues. Fluconazole at 25 mg/kg cured no infection in any tissue, whereas 25 mg of ravuconazole/kg cleared infection in all tissues from 50% of mice. Ravuconazole has good efficacy and the potential to cure mucosal candidosis in the absence of a functional immune response.

* Corresponding author. Mailing address: Division of Infectious Diseases, Dept. of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Ave. San Jose, CA 95128-2699. Phone: (408) 998-4557. Fax: (408) 998-2723. E-mail: clemons{at}cimr.org.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3433-3436, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3433-3436.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Coste, A., Lagane, C., Filipe, C., Authier, H., Gales, A., Bernad, J., Douin-Echinard, V., Lepert, J.-C., Balard, P., Linas, M.-D., Arnal, J.-F., Auwerx, J., Pipy, B. (2008). IL-13 Attenuates Gastrointestinal Candidiasis in Normal and Immunodeficient RAG-2-/- Mice via Peroxisome Proliferator-Activated Receptor-{gamma} Activation. J. Immunol. 180: 4939-4947 [Abstract] [Full Text]  
  • Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
  • Clemons, K. V., Gonzalez, G. M., Singh, G., Imai, J., Espiritu, M., Parmar, R., Stevens, D. A. (2006). Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.. Antimicrob. Agents Chemother. 50: 2650-2657 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A., Sarafandi, A., Wuerthwein, G., Bacher, J., Walsh, T. J. (2005). Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 56: 899-907 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2004). In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother. 48: 3107-3111 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»